# Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers

> **NCT02194283** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ambroxol - in single rising doses
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02194283
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2009-11
- **Final completion:** —
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194283, "Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02194283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*